Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial.

Cancers (Basel) · 2022 · PMC9100924 · PMID 35565404

Europe PMC DOI

hedged sentences

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

showed a trendp = 5.9 × 10 −2so close (0.05 < p ≤ 0.1)

The comparison between both groups showed a trend towards better DC rate in the “matched therapy group” ( p = 5.9 × 10 −2 ).

also in 53,322 other papers

a strong trendno p-value reported

However, even if our results about efficacy are significant, we acknowledge that our study displays limitations, including the small number of patients in the compared groups with 12 patients in the “matched therapy group”, and 25 in the “non-matched therapy group”, and the imbalance of characteristics between these groups with a strong trend for more patients with PC in the first one (83%) than in the second one (44%).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.